<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03911102</url>
  </required_header>
  <id_info>
    <org_study_id>1820205</org_study_id>
    <nct_id>NCT03911102</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Increasing Doses of DaxibotulinumtoxinA for Injection (DAXI for Injection) in the Treatment of Moderate or Severe Lateral Canthal Lines</brief_title>
  <official_title>A Phase 2a, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Efficacy, Safety, and Duration of Benefit of Increasing Doses of DaxibotulinumtoxinA for Injection (DAXI for Injection) in the Treatment of Moderate or Severe Lateral Canthal Lines</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Revance Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Revance Therapeutics, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 2a, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Treatment of
      Moderate or Severe Lateral Canthal Lines.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 11, 2019</start_date>
  <completion_date type="Actual">April 23, 2020</completion_date>
  <primary_completion_date type="Actual">April 23, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence, severity, and relationship to study drug of treatment-emergent AEs (TEAEs) and serious adverse events (SAEs)</measure>
    <time_frame>Baseline-Week 36</time_frame>
    <description>Number of participants with TEAEs and SAEs will be evaluated (safety and tolerability)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects achieving a score of 0 or 1 (none or mild) in LCL severity on the Investigator Global Assessment Lateral Canthal Wrinkle Severity scale</measure>
    <time_frame>Baseline-Week 36</time_frame>
    <description>Evaluate the efficacy of DAXI for injection using the proportion of subjects achieving a score of 0 or 1 (none or mild) in LCL severity on the Investigator Global Assessment Lateral Canthal Wrinkle Severity (IGA-LCWS) scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The responder rate of DAXI for injection in the treatment of LCL</measure>
    <time_frame>Baseline-Week 36</time_frame>
    <description>The responder rate is determined by the proportion of subjects achieving a score of 0 or 1 (none or mild) in LCL severity at maximum smile on the PLCWS scale at 4 weeks after LCL treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The responder rate of DAXI for injection in the treatment of LCL</measure>
    <time_frame>Baseline-Week 36</time_frame>
    <description>The responder rate is determined by the proportion of subjects achieving an improvement of at least 1 point from baseline in LCL severity at maximum smile on the IGA-LCWS at Week 4 after LCL treatment</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Lateral Canthal Lines</condition>
  <arm_group>
    <arm_group_label>Cohort 1: DaxibotulinumtoxinA Dose A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive Dose A of DaxibotulinumtoxinA for injection for the treatment of moderate to severe LCL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: DaxibotulinumtoxinA Dose B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive Dose B of DaxibotulinumtoxinA for injection for the treatment of moderate to severe LCL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: DaxibotulinumtoxinA Dose C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive Dose C of DaxibotulinumtoxinA for injection for the treatment of moderate to severe LCL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: DaxibotulinumtoxinA Dose D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive Dose D of DaxibotulinumtoxinA for injection for the treatment of moderate to severe LCL</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DaxibotulinumtoxinA for injection</intervention_name>
    <description>Intramuscular injection</description>
    <arm_group_label>Cohort 1: DaxibotulinumtoxinA Dose A</arm_group_label>
    <arm_group_label>Cohort 2: DaxibotulinumtoxinA Dose B</arm_group_label>
    <arm_group_label>Cohort 3: DaxibotulinumtoxinA Dose C</arm_group_label>
    <arm_group_label>Cohort 4: DaxibotulinumtoxinA Dose D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provide written informed consent consistent with International Conference on
             Harmonisation (ICH)-Good Clinical Practice (GCP) guidelines and local laws, including
             authorization to release health information, signed prior to any study procedures
             being performed

          -  Be outpatient, male or female subjects, in good general health, 18-65 years old

          -  Have a score of moderate (2) or severe (3) LCL at maximum smile effort as assessed by
             the IGA-LCWS

          -  Able to understand the requirements of the study and be willing and able to follow all
             study procedures, attend all scheduled visits, and successfully complete the study.

        Exclusion Criteria:

          -  Active skin disease, infections, or inflammation at the injection sites

          -  History of clinically significant bleeding disorders

          -  Clinically significant laboratory values at screening that may interfere with a
             subject's ability to complete the study, as determined by the investigator

          -  Planned or anticipated need for surgery or hospitalization through the end of the
             study

          -  Pregnant, nursing, or planning a pregnancy during the study; or is WOCBP but is not
             willing to use an effective method of contraception

          -  Current enrollment in an investigational drug or device study or participation in such
             a study within the last 30 days prior to screening through the end of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dom Vitarella</last_name>
    <role>Study Director</role>
    <affiliation>Revance Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sacramento, CA Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarasota, FL Site</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Itasca, IL Site</name>
      <address>
        <city>Itasca</city>
        <state>Illinois</state>
        <zip>60143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arlington, VA Site</name>
      <address>
        <city>Arlington</city>
        <state>Virginia</state>
        <zip>22209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>March 27, 2019</study_first_submitted>
  <study_first_submitted_qc>April 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2019</study_first_posted>
  <last_update_submitted>May 8, 2020</last_update_submitted>
  <last_update_submitted_qc>May 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lateral canthal wrinkle</keyword>
  <keyword>Crow's feet lines</keyword>
  <keyword>LCL</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

